Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT05054218 Completed - Covid19 Clinical Trials

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

Start date: September 10, 2021
Phase:
Study type: Observational

Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2 vaccine among cancer patients receiving the recommended third vaccine dose

NCT ID: NCT05054127 Not yet recruiting - Covid19 Clinical Trials

Clinical Characteristics And Outcome Of COVID-19 Infection In Patients With Chronic Respiratory Diseases.

Start date: April 15, 2022
Phase:
Study type: Observational [Patient Registry]

1. To identify the pattern of presentation of COVID-19 in patients with chronic respiratory diseases 2. To asses the severity of COVID-19 in patients with chronic respiratory diseases 3. To identify the outcome of COVID-19 in patients with chronic respiratory diseases

NCT ID: NCT05054114 Completed - Clinical trials for COVID-19 Respiratory Infection

Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19

Start date: December 21, 2020
Phase: N/A
Study type: Interventional

It is known that the pretreatment with exogenous interferon blocks SARS-CoV-2 infection, but intervention is much more effective if administered prior to infection. In this study the primary aim is to investigate 28-day regime of nasal interferon gama use in healthy participants for COVID-19 and other respiratory infections prevention.

NCT ID: NCT05054088 Completed - Covid19 Clinical Trials

ImmuneSense COVID-19 Variant Study

Start date: October 12, 2021
Phase:
Study type: Observational

This study will assess the clinical performance of the T-Detect™ COVID test to identify an immune response to SARS-CoV-2 infection in the setting of multiple circulating variants of the SARS-CoV-2 virus. Performance may vary depending on the variants circulating at the time of testing, including newly emerging strains of SARS-CoV-2 and their prevalence, which changes over time.

NCT ID: NCT05054075 Enrolling by invitation - COVID-19 Clinical Trials

Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The present work proposes to find if a bio-active composite in the hemolymph or plasma of the freshwater bivalve Anodonta cygnea is able to offer immunity and specificity for meliorating the major symptoms in human SARS and COVID-19 lineage infection. The Methodology concerns in silico procedures using organic fluids from 54 bivalves (in very specific conditions) to evaluate their therapeutic effects in 6 voluntary SARS and COVID-19 infected persons with an integrative diagnosis by a computational Mora®Nova apparatus to access the basal and experimental human physiological parameters.

NCT ID: NCT05052580 Completed - Covid19 Clinical Trials

Test to Stay in School: COVID-19 Testing Following Exposure in School Communities

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Participants in school communities who have been exposed to SARS-CoV-2 will be tested for COVID-19 on the day of exposure (day 1) and at days 3, 5, and 7 following initial known exposure. Mitigation practices including masking, the context of exposure (classroom, school bus, after school sporting event, lunch, etc.), and results of COVID-19 test will be documented.

NCT ID: NCT05052346 Completed - Covid19 Clinical Trials

Association of the Neutrophil/Lymphocyte Ratio With Pulmonary Complications and Mortality in COVID-19 Patients

Start date: March 30, 2020
Phase:
Study type: Observational [Patient Registry]

The Coronavirus Disease-19 (COVID-19) pandemic is currently a priority for health services worldwide. Unlike the Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) epidemic in 2012, the COVID-19 shows specific alterations in the white blood cell count, accentuated in severe cases, and with respiratory failure. Among the most relevant data are both lymphopenia, thrombocytopenia, and eosinopenia. The Neutrophil Lymphocyte Index has been beneficial in the evaluation of infectious respiratory processes, showing a sensitivity similar to scales such as CURB65 (Confusion, Uremia, Respiratory rate, BP, age ≥ 65 years). Because COVID-19 infection shows alterations in the blood cell ratio, these indices may be useful in evaluating patients with COVID-19 infection.

NCT ID: NCT05052333 Completed - COVID-19 Pandemic Clinical Trials

Examine the Psychosocial Impacts of COVID-19 Pandemic.

Start date: December 1, 2021
Phase:
Study type: Observational

This is an observational study examining the psychosocial impacts of the COVID-19 pandemic in seven low-and-middle income countries (Indonesia, Iran, Iraq, Malaysia, Pakistan, Somaliland, and Turkiye). The data was obtained on standardised measures of wellbeing (WHO Well-Being Index), psychological distress (Kessler 10), post-traumatic stress (PTSD Checklist for DSM-5), post-traumatic growth (Posttraumatic Growth Inventory), and a novel pandemic-related stress (COVID Psychosocial Impacts Scale). Data was collected employing either a unilingual (in native language) or bilingual online survey (with English as a second language) from participants (N=2574) aged 18 and above using a non-probability convenient sampling. The findings enabled us to examine the psychosocial impacts of COVID-19, validate the translations of the CPIS and standardized measures; and determine the trajectory of study variables with pandemic exposure.

NCT ID: NCT05052320 Not yet recruiting - Covid 19 Clinical Trials

Audiological Assessment of Recovered Covid 19 Subjects.

Start date: October 2021
Phase:
Study type: Observational [Patient Registry]

To assess the audiological profile in recovered covid 19 subjects in comparison with control group.

NCT ID: NCT05052307 Completed - Covid19 Clinical Trials

A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil

Start date: November 3, 2021
Phase:
Study type: Observational

The present test-negative design study aims to estimate the real-world effectiveness of Pfizer-BioNTech BNT162b2 mRNA vaccine on symptomatic SARS-CoV-2 infection and its consequences following a mass vaccination campaign in the city of Toledo in Southern Brazil. Individuals aged 12 years or older who seek the public healthcare system with symptoms suggestive COVID-19 will be enrolled. Participants with a positive polymerase chain reaction (PCR) test for SARS-CoV-2 will be classified as cases, and those with negative PCR test for SARS-CoV-2 will be classified as controls. Cases will be followed-up for a period of one year by means of structured telephone interviews.